Statements (33)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:antibiotic
immunosuppressant |
| gptkbp:administeredBy |
oral
topical intravenous |
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA |
| gptkbp:associatedWith |
gptkb:cyclosporine
gptkb:pimecrolimus |
| gptkbp:ATCCode |
L04AD02
|
| gptkbp:CASNumber |
104987-11-3
|
| gptkbp:discoveredBy |
gptkb:Fujisawa_Pharmaceutical_Co.
|
| gptkbp:discoveredIn |
1987
|
| gptkbp:eliminationHalfLife |
12 hours
|
| gptkbp:foundIn |
gptkb:Streptomyces_tsukubaensis
|
| gptkbp:hasMolecularFormula |
C44H69NO12
|
| https://www.w3.org/2000/01/rdf-schema#label |
Fujimycin
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
immunosuppressant
|
| gptkbp:metabolism |
gptkb:CYP3A4
liver |
| gptkbp:otherName |
gptkb:Tacrolimus
|
| gptkbp:PubChem_CID |
gptkb:CHEMBL521
445643 |
| gptkbp:sideEffect |
hypertension
nephrotoxicity neurotoxicity hyperglycemia |
| gptkbp:UNII |
WM5Z385K7T
|
| gptkbp:usedFor |
prevention of organ transplant rejection
treatment of eczema |
| gptkbp:bfsParent |
gptkb:Fujisawa_Pharmaceutical
|
| gptkbp:bfsLayer |
6
|